The stock of PolyPid Ltd. (NASDAQ:PYPD) last traded at $0.98, up 3.16% from the previous session.
Data from the available sources indicates that PolyPid Ltd. (NASDAQ:PYPD) is covered by 4 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $4.00 and a low of $2.50, we find $3.50. Given the previous closing price of $0.95, this indicates a potential upside of 268.42 percent. PYPD stock price is now 27.59% away from the 50-day moving average and -68.74% away from the 200-day moving average. The market capitalization of the company currently stands at $17.64M.
In total, 1 analysts have assigned it a hold rating, and 2 have given it a buy rating. Brokers who have rated the stock have averaged $3.38 as their price target over the next twelve months.
With the price target of $14, JMP Securities recently initiated with Mkt Outperform rating for PolyPid Ltd. (NASDAQ: PYPD). On July 30, 2021, Cantor Fitzgerald recently initiated its ‘Overweight’ rating on the stock quoting a target price of $24, while ‘Raymond James’ rates the stock as ‘Strong Buy’.
A total of 21.26% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PYPD stock. A new stake in PolyPid Ltd. shares was purchased by MILLENNIUM MANAGEMENT LLC during the first quarter worth $63,000. BOOTHBAY FUND MANAGEMENT, LLC invested $15,000 in shares of PYPD during the first quarter. In total, there are 32 active investors with 12.80% ownership of the company’s stock.
With an opening price of $0.9700 on Monday morning, PolyPid Ltd. (NASDAQ: PYPD) set off the trading day. During the past 12 months, PolyPid Ltd. has had a low of $0.65 and a high of $6.90. As of last week, the company has a debt-to-equity ratio of 1.00, a current ratio of 2.90, and a quick ratio of 2.90. The fifty day moving average price for PYPD is $0.7681 and a two-hundred day moving average price translates $3.1351 for the stock.
The latest earnings results from PolyPid Ltd. (NASDAQ: PYPD) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.61, beating analysts’ expectations of -$0.62 by 0.01. This compares to -$0.53 EPS in the same period last year. The company reported revenue of $8.76 million for the quarter, compared to $10.06 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -12.96 percent.
PolyPid Ltd.(PYPD) Company Profile
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.